Status and phase
Conditions
Treatments
About
SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Note: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study
Exclusion criteria
Subjects presenting with any of the following will not be included in the study:
Primary purpose
Allocation
Interventional model
Masking
23 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal